Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant regorafenib + nivolumab with short-course radiotherapy in stage II–III rectal cancer
2020-000876-40Phase 2Active
- Sponsor
- Institut Jules Bordet
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of regorafenib and nivolumab in rectal cancer, sponsored by Institut Jules Bordet. Primary endpoint: Complete response rate. Started Nov 2020; status: active.
02
Drugs
regorafenibnivolumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2020-000876-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000876-40.